Suppr超能文献

口服利托君与葡萄糖酸镁用于门诊保胎治疗的比较。

Comparison of oral ritodrine and magnesium gluconate for ambulatory tocolysis.

作者信息

Martin R W, Martin J N, Pryor J A, Gaddy D K, Wiser W L, Morrison J C

机构信息

Department of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson 39216-4505.

出版信息

Am J Obstet Gynecol. 1988 Jun;158(6 Pt 1):1440-5. doi: 10.1016/0002-9378(88)90379-1.

Abstract

Magnesium sulfate has been administered intravenously to arrest preterm labor but the oral form of this drug cannot be used for continual tocolysis. This trial involved the administration of oral magnesium gluconate to determine its effectiveness compared with that of ritodrine hydrochloride in 50 patients whose labor had been arrested by parenteral therapy. Group A (n = 25) received 1 gm of oral magnesium gluconate every 2 to 4 hours for tocolysis and group B (n = 25) received 10 mg of ritodrine every 2 to 4 hours. The number of patients who progressed to 37 weeks' gestation was similar (group A, 21 versus group B, 19) and the time gained in utero was not different (group A, 6.4 weeks versus group B, 5.9 weeks). There was a trend toward more side effects with the use of ritodrine (40%) compared with magnesium gluconate (16%), but the numbers were too small to reveal a significant difference. These data suggest that magnesium gluconate used as an oral tocolytic is as effective as a beta-agonist in patients whose labor is arrested initially with intravenous therapy.

摘要

硫酸镁已被静脉注射用于抑制早产,但该药物的口服剂型不能用于持续的宫缩抑制治疗。本试验对50例已通过肠外治疗抑制宫缩的患者给予口服葡萄糖酸镁,以确定其与盐酸利托君相比的有效性。A组(n = 25)每2至4小时接受1克口服葡萄糖酸镁进行宫缩抑制治疗,B组(n = 25)每2至4小时接受10毫克利托君治疗。孕周进展至37周的患者数量相似(A组21例,B组19例),子宫内孕周增加时间无差异(A组6.4周,B组5.9周)。与葡萄糖酸镁(16%)相比,使用利托君(40%)出现更多副作用的趋势,但样本量太小,无法显示出显著差异。这些数据表明,对于最初通过静脉治疗抑制宫缩的患者,口服葡萄糖酸镁作为宫缩抑制剂与β-激动剂一样有效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验